Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06178211
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-20
First Post:
2023-11-18
Brief Title:
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC a Single Arm Prospective Phase 2 Clinical Trial
Sponsor:
Shanghai Chest Hospital
Organization:
Shanghai Chest Hospital
Study Overview
Official Title:
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC a Single Arm Prospective Phase 2 Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab SHR-1316 and chemotherapy in patients with resectable esophageal squamous cell carcinoma ESCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None